CELC | tickerfilter.com

Fundamental analysis

31%

Profitability 25%

Dept financing 8%

Liquidity 42%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.50%

1 Month

-10.46%

3 Months

-27.87%

6 Months

-39.97%

1 Year

-53.27%

2 Year

-8.63%

Key data

Stock price

$9.16

P/E Ratio

0.00

DAY RANGE

$7.70 - $9.18

EPS

-$2.61

52 WEEK RANGE

$7.70 - $19.87

52 WEEK CHANGE

-$53.97

MARKET CAP

552.098 M

YIELD

N/A

SHARES OUTSTANDING

37.030 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-14-2025

BETA

1.38

PUBLIC FLOAT

AVERAGE 10 VOLUME

$720,558

AVERAGE 30 VOLUME

$341,007

Company detail

CEO: Brian F. Sullivan
Region: US
Website: celcuity.com
Employees: 40
IPO year: 2017

Issue type: Common Stock
Market: XNAS
Industry: Healthcare/Services – Health
Sector: Services

Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.

CELC - Celcuity Inc.